Bosentan, Catalog: B1857

Alternate Names 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-benzenesulfonamide; Ro 47-0203

Appearance White solid

CAS # 147536-97-8

Molecular Formula C₂₇H₂₉N₅O₆S

Molecular Weight 551.61

Purity ≥ 98% by HPLC

Solubility DMSO (>40 mg/ml) or EtOH (>20 mg/ml)

SMILES CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC

InChi nChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)

InChi Key GJPICJJJRGTNOD-UHFFFAOYSA-N

PubChem CID 104865

Storage Conditions -20°C

Shipping Conditions Gel Pack

Usage For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.

Bosentan is classified as an endothelin receptor antagonist, specifically targeting endothelin receptors type A (Ki = 6.5 nM) and type B (Ki = 340 nM). It is used in the treatment of pulmonary arterial hypertension (PAH) and other conditions associated with high blood pressure in the arteries of the lungs. It inhibits ET-1 induced contraction of isolated rat aorta and sarafotoxin S6C-induced contraction of rat trachea in vitro.